CHATSWORTH, Calif., Oct. 18, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Chairman, President and Chief Executive Officer, Cesar M. Garcia, will present an overview of the Company at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010, at 1:35 p.m. Eastern time at the Waldorf-Astoria Hotel in New York City.
Mr. Garcia and Amin Khalifa, newly appointed CFO, will also be available for one-on-one meetings with institutional investors at the conference throughout the day on Wednesday, November 3. Investors interested in scheduling a one-on-one meeting are asked to contact their Oppenheimer sales rep.
A webcast of Mr. Garcia's presentation will be available live and by replay. To access the live webcast, go to http://www.veracast.com/webcasts/opco/healthcare2010/09209552.cfm. The link will also be available on the Investor's page of the IRIS International, Inc. website at www.proiris.com. A replay of the presentation will be available approximately one hour following the live presentation and will be archived for 30 days.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,800 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.